vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and El Pollo Loco Holdings, Inc. (LOCO). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $126.2M, roughly 1.1× El Pollo Loco Holdings, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 6.5%, a 29.0% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 5.9%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 1.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
El Pollo Loco, Inc., is a restaurant chain based in the United States, specializing in Mexican-style grilled chicken. Restaurant service consists of dine-in and take-out, with some locations offering drive-through options. The company is headquartered in Costa Mesa, California, and operates about 500 company-owned and franchised restaurants in the Southwestern United States.
ADMA vs LOCO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $126.2M |
| Net Profit | $49.4M | $8.2M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 9.7% |
| Net Margin | 35.5% | 6.5% |
| Revenue YoY | 18.4% | 5.9% |
| Net Profit YoY | -55.9% | 48.8% |
| EPS (diluted) | $0.20 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $126.2M | ||
| Q4 25 | $139.2M | $123.5M | ||
| Q3 25 | $134.2M | $121.5M | ||
| Q2 25 | $122.0M | $125.8M | ||
| Q1 25 | $114.8M | $119.2M | ||
| Q4 24 | $117.5M | $114.3M | ||
| Q3 24 | $119.8M | $120.4M | ||
| Q2 24 | $107.2M | $122.2M |
| Q1 26 | — | $8.2M | ||
| Q4 25 | $49.4M | $6.5M | ||
| Q3 25 | $36.4M | $7.4M | ||
| Q2 25 | $34.2M | $7.1M | ||
| Q1 25 | $26.9M | $5.5M | ||
| Q4 24 | $111.9M | $6.0M | ||
| Q3 24 | $35.9M | $6.2M | ||
| Q2 24 | $32.1M | $7.6M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 45.1% | 8.3% | ||
| Q3 25 | 38.0% | 9.4% | ||
| Q2 25 | 35.1% | 9.0% | ||
| Q1 25 | 30.4% | 7.5% | ||
| Q4 24 | 32.6% | 7.9% | ||
| Q3 24 | 33.1% | 8.4% | ||
| Q2 24 | 36.6% | 10.1% |
| Q1 26 | — | 6.5% | ||
| Q4 25 | 35.5% | 5.3% | ||
| Q3 25 | 27.1% | 6.1% | ||
| Q2 25 | 28.1% | 5.6% | ||
| Q1 25 | 23.4% | 4.6% | ||
| Q4 24 | 95.2% | 5.2% | ||
| Q3 24 | 30.0% | 5.1% | ||
| Q2 24 | 29.9% | 6.2% |
| Q1 26 | — | $0.27 | ||
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $0.15 | $0.25 | ||
| Q2 25 | $0.14 | $0.24 | ||
| Q1 25 | $0.11 | $0.19 | ||
| Q4 24 | $0.45 | $0.21 | ||
| Q3 24 | $0.15 | $0.21 | ||
| Q2 24 | $0.13 | $0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $3.9M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $302.5M |
| Total Assets | $624.2M | $609.1M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.9M | ||
| Q4 25 | $87.6M | $6.2M | ||
| Q3 25 | $61.4M | $10.9M | ||
| Q2 25 | $90.3M | $9.0M | ||
| Q1 25 | $71.6M | $4.3M | ||
| Q4 24 | $103.1M | $2.5M | ||
| Q3 24 | $86.7M | $7.9M | ||
| Q2 24 | $88.2M | $10.5M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $51.0M | ||
| Q3 25 | $72.4M | $61.0M | ||
| Q2 25 | — | $69.0M | ||
| Q1 25 | — | $73.0M | ||
| Q4 24 | $72.3M | $71.0M | ||
| Q3 24 | — | $76.0M | ||
| Q2 24 | — | $87.0M |
| Q1 26 | — | $302.5M | ||
| Q4 25 | $477.3M | $291.1M | ||
| Q3 25 | $431.2M | $282.9M | ||
| Q2 25 | $398.3M | $274.2M | ||
| Q1 25 | $373.4M | $265.7M | ||
| Q4 24 | $349.0M | $260.7M | ||
| Q3 24 | $231.9M | $255.2M | ||
| Q2 24 | $188.3M | $248.6M |
| Q1 26 | — | $609.1M | ||
| Q4 25 | $624.2M | $606.6M | ||
| Q3 25 | $568.7M | $602.7M | ||
| Q2 25 | $558.4M | $596.8M | ||
| Q1 25 | $510.6M | $590.5M | ||
| Q4 24 | $488.7M | $592.0M | ||
| Q3 24 | $390.6M | $590.0M | ||
| Q2 24 | $376.4M | $593.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 0.18× | ||
| Q3 25 | 0.17× | 0.22× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | 0.21× | 0.27× | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $13.9M | ||
| Q3 25 | $13.3M | $15.3M | ||
| Q2 25 | $21.1M | $14.1M | ||
| Q1 25 | $-19.7M | $4.7M | ||
| Q4 24 | $50.2M | $5.6M | ||
| Q3 24 | $25.0M | $13.0M | ||
| Q2 24 | $45.6M | $17.0M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $5.1M | ||
| Q3 25 | $-1.1M | $9.9M | ||
| Q2 25 | $18.7M | $9.1M | ||
| Q1 25 | $-24.4M | $1.3M | ||
| Q4 24 | $47.5M | $1.1M | ||
| Q3 24 | $24.0M | $9.1M | ||
| Q2 24 | $43.6M | $10.4M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 4.1% | ||
| Q3 25 | -0.8% | 8.2% | ||
| Q2 25 | 15.3% | 7.2% | ||
| Q1 25 | -21.2% | 1.1% | ||
| Q4 24 | 40.4% | 1.0% | ||
| Q3 24 | 20.0% | 7.6% | ||
| Q2 24 | 40.7% | 8.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 7.1% | ||
| Q3 25 | 10.7% | 4.4% | ||
| Q2 25 | 2.0% | 4.0% | ||
| Q1 25 | 4.1% | 2.8% | ||
| Q4 24 | 2.3% | 3.9% | ||
| Q3 24 | 0.9% | 3.2% | ||
| Q2 24 | 1.9% | 5.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 2.13× | ||
| Q3 25 | 0.36× | 2.08× | ||
| Q2 25 | 0.62× | 1.99× | ||
| Q1 25 | -0.73× | 0.86× | ||
| Q4 24 | 0.45× | 0.95× | ||
| Q3 24 | 0.70× | 2.11× | ||
| Q2 24 | 1.42× | 2.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
LOCO
Segment breakdown not available.
